The comment period for the FDA’s Draft Guidance Considerations in Demonstrating Interchangeability With a Reference Product (Docket FDA-2017-D-0154) ended on May 19, 2017. The 52 comments were submitted by manufacturers of biologics and biosimilars, third-party payers, pharmacy trade associations, and patient groups.
While most commenters congratulated the FDA on its flexible approach to interchangeability, many called on the agency to provide additional details about requirements for switching studies, the distinction between interchangeability and biosimilarity, guidelines for the use of foreign reference drugs in switching studies, and the requirements for showing interchangeability among all indications and all presentations. Commenters raised questions about what interchangeability truly means, and asked whether interchangeability should be interpreted as a higher standard or simply as an additional data requirement.
The FDA’s draft guidance called on biosimilar manufacturers to use so-called switching studies to determine the safety and efficacy of a biosimilar with respect to its reference product. Such studies would require that the comparator product should not be used as a control only, but should instead be used in both the active (switching) arm and the control (non-switching) arm of switching studies.
Furthermore, the guidance notes that using a non-US-licensed comparator product would not generally be appropriate. In its commentary, Pfizer disagreed with that recommendation, saying that such a practice has the potential to create practical challenges regarding where a switching study could be conducted; the Biosimilars Forum also said this aspect of the guidance could undermine the global nature of biosimilar development.
Many commenters expressed concern over whether the FDA will use labeling, nonproprietary naming, or another naming method that would indicate that a biosimilar is interchangeable. For example, the Hematology/Oncology Pharmacy Association (HOPA) said, “Considering that there may be differences in the criteria used to approve the drug, differences in approved indications, and differences in immunogenicity, it is important to have a name that allows providers to differentiate which drug they are actually using, or switching to.” HOPA underscored its previous recommendation that the drug name consist of the reference drug’s International Nonproprietary Name (INN) plus a meaningful suffix, and said the current FDA position of using an INN plus a random suffix is both confusing and unsafe.
Some commenters asked the FDA to explain its plan for post-marketing changes to reference drugs after findings of interchangeability. Commenters also requested greater clarity and clearer direction from the FDA regarding interchangeability and multiple applications, given the abbreviated process for generic drug approvals and continuing confusion about the language of the Biologics Price Competition and Innovations Act [BPCIA], a legal quandary that has made its way to the Supreme Court for clarification).
AARP, Inc, which represents 38 million Americans over age 50, also weighed in, saying that the biosimilar approval pathway will only be fully utilized if the requirements for biosimilar approval are reduced relative to requirements for a traditional biologic license application. “If not,” says the organization, “companies could forgo biosimilar development entirely. Given manufacturers’ clear and growing interest in developing biologic drugs, it is difficult to overstate how much this outcome would negatively affect patients, payers, and taxpayers.” AARP’s overriding concern is that the BPCIA be implemented in a manner that ensures safety and efficacy without creating unnecessary barriers to the savings promised by the biosimilar approval pathway.
Comments on the FDA's Biosimilar Interchangeability Draft Guidance Highlight a Growing Need for Clarity
The comment period for the FDA’s Draft Guidance Considerations in Demonstrating Interchangeability With a Reference Product (Docket FDA-2017-D-0154) ended on May 19, 2017. The 52 comments were submitted by manufacturers of biologics and biosimilars, third-party payers, pharmacy trade associations, and patient groups.
While most commenters congratulated the FDA on its flexible approach to interchangeability, many called on the agency to provide additional details about requirements for switching studies, the distinction between interchangeability and biosimilarity, guidelines for the use of foreign reference drugs in switching studies, and the requirements for showing interchangeability among all indications and all presentations. Commenters raised questions about what interchangeability truly means, and asked whether interchangeability should be interpreted as a higher standard or simply as an additional data requirement.
The FDA’s draft guidance called on biosimilar manufacturers to use so-called switching studies to determine the safety and efficacy of a biosimilar with respect to its reference product. Such studies would require that the comparator product should not be used as a control only, but should instead be used in both the active (switching) arm and the control (non-switching) arm of switching studies.
Furthermore, the guidance notes that using a non-US-licensed comparator product would not generally be appropriate. In its commentary, Pfizer disagreed with that recommendation, saying that such a practice has the potential to create practical challenges regarding where a switching study could be conducted; the Biosimilars Forum also said this aspect of the guidance could undermine the global nature of biosimilar development.
Many commenters expressed concern over whether the FDA will use labeling, nonproprietary naming, or another naming method that would indicate that a biosimilar is interchangeable. For example, the Hematology/Oncology Pharmacy Association (HOPA) said, “Considering that there may be differences in the criteria used to approve the drug, differences in approved indications, and differences in immunogenicity, it is important to have a name that allows providers to differentiate which drug they are actually using, or switching to.” HOPA underscored its previous recommendation that the drug name consist of the reference drug’s International Nonproprietary Name (INN) plus a meaningful suffix, and said the current FDA position of using an INN plus a random suffix is both confusing and unsafe.
Some commenters asked the FDA to explain its plan for post-marketing changes to reference drugs after findings of interchangeability. Commenters also requested greater clarity and clearer direction from the FDA regarding interchangeability and multiple applications, given the abbreviated process for generic drug approvals and continuing confusion about the language of the Biologics Price Competition and Innovations Act [BPCIA], a legal quandary that has made its way to the Supreme Court for clarification).
AARP, Inc, which represents 38 million Americans over age 50, also weighed in, saying that the biosimilar approval pathway will only be fully utilized if the requirements for biosimilar approval are reduced relative to requirements for a traditional biologic license application. “If not,” says the organization, “companies could forgo biosimilar development entirely. Given manufacturers’ clear and growing interest in developing biologic drugs, it is difficult to overstate how much this outcome would negatively affect patients, payers, and taxpayers.” AARP’s overriding concern is that the BPCIA be implemented in a manner that ensures safety and efficacy without creating unnecessary barriers to the savings promised by the biosimilar approval pathway.
As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount
Pharmacists play an essential role in counseling patients on biosimilar substitution protocols and following state regulations regarding interchangeable medications.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
FDA Approves Third Pair of Denosumab Biosimilars
The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases.
As Biosimilar Substitutions Become More Common, Education and Patient Counseling Are Paramount
Pharmacists play an essential role in counseling patients on biosimilar substitution protocols and following state regulations regarding interchangeable medications.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
FDA Approves Third Pair of Denosumab Biosimilars
The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat osteoporosis and bone metastases.